Provided by Tiger Trade Technology Pte. Ltd.

Iambic Therapeutics

23.81
+4.9025.91%
Post-market: 24.000.1900+0.80%19:59 EDT
Volume:2.96M
Turnover:67.77M
Market Cap:1.13B
PE:-11.98
High:25.00
Open:19.31
Low:19.31
Close:18.91
52wk High:25.00
52wk Low:16.15
Shares:47.40M
Float Shares:9.40M
Volume Ratio:1.47
T/O Rate:31.54%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9880
EPS(LYR):-3.5749
ROE:-54.21%
ROA:-29.35%
PB:-4.85
PE(LYR):-6.66

Loading ...

Company Profile

Company Name:
Iambic Therapeutics
Exchange:
NASDAQ
Establishment Date:
2019
Employees:
171
Office Location:
5627 Oberlin Drive,Suite 120,San Diego,California,United States
Zip Code:
92121
Fax:
- -
Introduction:
Iambic Therapeutics, Inc. is a technology and clinical-stage life sciences company using its Molecular Transformer and proprietary molecular intelligence platform to transform biopharmaceutical discovery. The platform combines large-scale artificial intelligence with automated, scalable chemistry and biology experiments to discover and develop novel medicines.

Directors

Name
Position
Thomas Miller
Chief Executive Officer and Director
Frederick Manby
Chief Technology Officer and Director
Evan Rachlin
Director
Kurt von Emster
Director
Mary Tagliaferri
Director
R. Jacob Vogelstein
Director
Samit Hirawat
Director
Shalini Sharp
Director
William Rastetter
Director

Shareholders

Name
Position
Thomas Miller
Chief Executive Officer and Director
Michael Secora
Chief Corporate Development Officer and Chief Financial Officer
Frederick Manby
Chief Technology Officer and Director
Neil Josephson
Chief Medical Officer
Peter Olson
Chief Scientific Officer